Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Status:
Terminated
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph
pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment
of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin
(POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in
pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and
monthly visits on therapy will monitor plasma levels of POMC, other pituitary function,
safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic
resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The
eligible patient population will consist of adult patients with known silent corticotroph
pituitary tumors and elevated plasma levels of POMC.